Please ensure Javascript is enabled for purposes of website accessibility

I-Mab executes senior management team’s share purchase plan

I-Mab, a Gaithersburg clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, Friday announced the senior management team of the company, including founder, chairman and acting CEO Dr. Jingwu Zang, President Dr. Andrew Zhu, Chief Financial Officer John Long, Chief Strategy Officer Jielun Zhu and Chief Business Officer Dr. Weimin Tang, have executed the share purchase plan with the open market purchase of more than 70,000 of the Company’s American depositary shares  for more than $2.6 million.

The average price per ADS is approximately $38. The senior management team plans to continue to purchase the company’s ADSs on the open market for an minimum $3 million and up to $20 million on an accumulative basis.

1 of 1 article

0 articles remaining

Grow your business intelligence with The Daily Record. Register now for more article access.

Leave a Reply

Your email address will not be published. Required fields are marked *